| Literature DB >> 28844606 |
Christina Alves Peixoto1, Wilma Helena de Oliveira2, Shyrlene Meiry da Racho Araújo2, Ana Karolina Santana Nunes3.
Abstract
Adenosine monophosphate-activated protein kinase (AMPK) is an evolutionarily conserved sensor of cellular energy status and has been reported to be involved in chronic inflammatory disorders. AMPK is expressed in immune cells, such as dendritic cells, macrophages, lymphocytes and neutrophils, and is an important regulator of inflammatory responses through the regulation of complex signaling networks in part by inhibiting downstream cascade pathways, such as nuclear factor kB, which is a key regulator of innate immunity and inflammation, as well as acting as a negative regulator of toll-like receptors. Recent data suggest that AMPK dysregulation may participate in neurodegenerative diseases, such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and neuropathies. However, there are conflicting reports on the benefits or detrimental effects of AMPK in distinct pathological conditions. This paper offers a review of the recent literature on the pharmacological modulation of the AMPK system as a potential molecular target in the management of neurodegenerative diseases.Entities:
Keywords: AMPK activators; AMPK signaling; Neurodegeneration; Neuroinflammation
Mesh:
Substances:
Year: 2017 PMID: 28844606 DOI: 10.1016/j.expneurol.2017.08.013
Source DB: PubMed Journal: Exp Neurol ISSN: 0014-4886 Impact factor: 5.330